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Summary 
BACKGROUND: Vitamin B12 (VB12) deficiency can be treated with oral 
high-dose substitution or intramuscular (i.m.) injection of VB12. 
Whenever alternative routes of administration exist, patient prefer-
ences should be considered when choosing the treatment. We aimed 
to assess outpatient preferences towards oral or IM VB12 substitution 
and confirm noninferiority of early biomarker response with oral treat-
ment, in a typical primary care population. 
METHODS: Prospective randomised nonblinded parallel-group trial. 
Patients were recruited by their general practitioner and randomly as-
signed to oral or IM treatment. Group O-oral was given 28 tablets of 
1000 µg cyanocobalamin in a monthly punch card fitted with an elec-
tronic monitoring system. Group I-IM received four, weekly injections 
of 1000 µg hydroxocobalamin. Blood samples were drawn before the 
first administration and after 1, 2 and 4 weeks of treatment, and ana-
lysed for VB12, holotranscobalamin (HoloTc), homocysteine (Hcy) and 
methylmalonic acid (MMA). For group O-oral, treatment adherence 
and percentage of days with 2 dosing events were calculated. Before 
and after 28 days of treatment, patients were asked to fill in a ques-
tionnaire about their preference for the therapy options and associ-
ated factors. 
RESULTS: Between November 2013 and December 2015, 37 patients 
(age: 49.5 ± 18.5 years; women: 60.5%) were recruited for oral (19) or 
IM (18) treatment. Baseline values with 95% confidence intervals for 
serum VB12, HoloTc, Hcy and MMA were 158 pmol/l [145–172], 49.0 
pmol/l [40.4–57.5], 14.8 µmol/l [12.0–17.7] and 304 nmol/l [219–390], 
respectively, in group O-oral and 164 pmol/l [154–174], 50.1 pmol/l 
[38.7–61.6], 13.0 µmol/l [11.0–15.1] and 321 nmol/l [215–427], re-
spectively, in group I-IM (not significant). After 1 month of treatment, 
levels of VB12 and HoloTc showed a significant increase compared 
with baseline (group O-oral: VB12 354 pmol/l [298–410] and HoloTc 
156 pmol/l [116–196]; group I-IM: VB12 2796 pmol/l [1277–4314] and 
HoloTc 1269 pmol/l [103–2435]). Hcy and MMA levels showed a sig-
nificant decrease compared with baseline (group O-oral: Hcy 
13.8 µmol/l [10.7–16.8] and MMA 168 nmol/l [134–202]; group I-IM: 
Hcy 8.5 µmol/l [7.1–9.8] and MMA 156 nmol/l [121–190]). HoloTc and 
MMA levels were normalised in all patients after 4 weeks of treat-
ment, whereas normalisation of VB12 and Hcy was reached by all pa-
tients in group I-IM only. Response of VB12, HoloTc and Hcy was more 
pronounced in group I-IM (p <0.01) and the primary hypothesis that 
oral VB12 treatment would be noninferior to IM treatment was re-
jected. Average adherence to therapy was 99.6 ± 1.1% and days with 
2 dosing events reached 5.6%. Before randomisation, preference was 
in favour of oral treatment (45.9%, n = 17) over IM administration 
(21.6%, n = 8). Twelve patients (32.4%) had no preference. Nine 
(24.3%) patients changed their preference after treatment. Patients 
who obtained their preferred route of administration maintained their 
preference in the case of oral treatment and changed their preference 
after IM treatment. 
CONCLUSIONS: Differences in VB12 levels between groups were 
higher than expected. Therefore, noninferiority of oral treatment had 
to be rejected. However, normalisation of HoloTc and MMA was 
reached by all patients after a 1-month treatment period. The clinical 
benefit of the exaggerated biomarker response after IM treatment 
within a typical primary care population is questionable. Midterm bi-
omarker effects and patient preferences should be considered when a 
therapeutic scheme is chosen. Initial rating in favour of either IM or 
oral therapy can change over time and justifies repeated re-evaluation 
of patient preferences. (ClinicalTrials.gov ID NCT01832129) 
Background 
Depending on the definition used, prevalence of vitamin B12 (VB12) 
deficiency is 8–16% and 5–40% in adults (26–64 years) [1] and the el-
derly [2], respectively. However, the true prevalence of VB12 defi-
ciency in the general population is still uncertain, but it is known to rise 
with age, probably because of impaired absorption [3, 4]. 
Causes of VB12 deficiency can be divided into nutritional [5, 6], mal-
absorption syndromes and other gastrointestinal causes [5]. Pernicious 
anaemia typically presents with haematological signs and is associated 
with antibodies to intrinsic factor and/or gastric parietal cells, but ac-
counts for only a small proportion of the observed cases of VB12 defi-
ciency [7]. Furthermore, defective transport mechanisms due to genetic 
factors account for a very small proportion of cases [8]. Long-term 
treatment with acid-lowering agents [9, 10] and metformin [11] may 
also play a role in the development of VB12 deficiency. 
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Clinical symptoms of VB12 deficiency are numerous. Besides nonspe-
cific symptoms such as tiredness and a loss of appetite, haematological 
manifestations (megaloblastic anaemia), neurological disorders (e.g., 
polyneuropathy, ataxia) and symptoms of a psychiatric nature (e.g., de-
pression) are possible [8, 12]. Additionally, cardiovascular manifesta-
tions, which accompany hyperhomocysteinaemia, are described [13–
16]. Because VB12 deficiency is a reversible cause of demyelinating 
nervous system disease and bone marrow failure, its early detection and 
treatment are important [12]. 
The indications for VB12 supplementation is VB12 deficiency of vari-
ous causes (e.g., pernicious anaemia, gastrectomy, dietary deficiency) 
[12]. In addition, preventive treatment should be initiated in pure vege-
tarians, pregnant women on a Mediterranean diet, patients with gastric 
surgery and nitrous oxide exposure [17]. However, there are no official 
threshold concentrations for initiating treatment. Biochemically, VB12 
deficiency is characterised by subnormal to borderline serum VB12 lev-
els. Holotranscobalamin (HoloTc) is the bioactive form of VB12 and 
has been discussed controversially as a more specific and sensitive 
marker of VB12 deficiency [18–20]. Functional VB12 deficiency is 
characterised by an increase of methylmalonic acid (MMA) and/or ho-
mocysteine (Hcy). Functional testing is recommended when VB12 de-
ficiency is highly expected, levels of serum VB12 are moderately low 
(148–221 pmol/l), in patients with unexplained macrocytosis or unex-
plained neurological issues, and when VB12 deficiency is highly sus-
pected to be a treatable cause of dementia [17]. Further laboratory find-
ings are haematological abnormalities such as macrocytosis, pancyto-
penia and hypersegmented neutrophils. Haematological changes can be 
found in the more severe cases, whereas biochemical findings go in par-
allel with less specific clinical manifestations of VB12 deficiency. 
However, no clear-cut limits exist for the prediction of symptoms [12]. 
Subclinical VB12 deficiency occurs and is found in up to 10–25% of 
the aged population. Treatment of these patients is common, even 
though the long-term benefits of such treatment are unclear [17]. 
The treatment of VB12 deficiency consists of VB12 supplementation, 
which can be either oral or by intramuscular (IM) injection. Patients 
with severe VB12 deficiency should receive injections of 1000 g 
VB12 at least several times per week for 1 to 2 weeks, then weekly until 
clear improvement is shown, followed by monthly injections [12, 17]. 
Initial oral treatment with high dose VB12 can be considered in patients 
with mild malabsorption or dietary deficiency [12]. Given the unpre-
dictable absorption of oral VB12, in severe cases the oral route should 
be used only after the serum VB12 level has been normalised with par-
enteral treatment or when the response to the treatment is monitored 
frequently with measurement of serum VB12 and MMA [17]. Meas-
urements for monitoring response to treatment after VB12 substitution 
comprise VB12 itself, its active fraction HoloTc and either Hcy or 
MMA as a functional marker (in the case of a mild form without hae-
matological manifestations), and potassium, iron status, lactate dehy-
drogenase and bilirubin (in cases of VB12-associated anaemia). 
In Switzerland, VB12 supplementation is predominantly given as IM 
injections [21], which are usually painful. No high-dose VB12 oral 
monopreparation is currently available, despite evidence of its effec-
tiveness [22–24]. Good response to oral supplementation has been ob-
served even in the presence of gastrointestinal diseases that are com-
monly associated with VB12 deficiency. One study showed that VB12 
deficiency could even be reversed in patients who had undergone gas-
trectomy [25]. However, evidence for the effectiveness of oral high-
dose VB12 substitution from randomised trials comparing oral and IM 
administration is limited [26]. 
Oral treatment with VB12 may be superior to IM injections in terms of 
patient acceptance and cost-effectiveness [27]. Patient preferences in 
treatment-related decisions should be elicited and taken into account, 
because patients who felt less empowered with regard to treatment de-
cisions reported lower rates of adherence [28]. Finally, a better under-
standing of patient preferences and values for making choices is funda-
mental to achieving shared decision-making and ultimately improving 
adherence. 
We aimed to assess outpatient preferences for VB12 supplementation 
by the oral or IM route, and to confirm noninferiority of early biomarker 
response with oral treatment in a typical primary-care population with 
biochemically defined VB12 deficiency. 
Material and methods 
This prospective, randomised, nonblinded parallel-group trial was ap-
proved by the ethics committee of the cantons Aargau and Solothurn, 
Switzerland, and has been registered at ClinicalTrials.gov ID 
NCT01832129. The study was conducted in accordance with the Dec-
laration of Helsinki and follows the International Conference on Har-
monisation Good Clinical Practice (ICH-GCP) guidelines. The primary 
hypothesis was that oral VB12 treatment would be noninferior to IM 
treatment in terms of serum VB12 response after 1 month of treatment. 
Patients were expected to prefer oral treatment over IM injections be-
fore and after treatment. 
Participants 
Recruitment was initiated at three general practitioner (GP) practices in 
the area of Olten, Switzerland. Eligible patients had a VB12 serum con-
centration <200 pmol/l, an indication for VB12 supplementation ac-
cording to their GP’s estimation, were 18 years old and were able to 
give written informed consent. Exclusion criteria were: the concurrent 
intake of vitamin preparations containing VB12, previously diagnosed 
dementia, known hereditary transcobolamin transportation defects, or 
lack of written and/or oral understanding of German, French, Italian or 
English. 
Recruitment 
A letter with the patient information leaflet and a written informed con-
sent form was given to patients whose physician had ordered a labora-
tory test for the biochemical confirmation of VB12 deficiency. Patients 
were asked to bring the informed consent form to their next scheduled 
visit with their GP, during which the results of the laboratory test would 
be discussed. Eligible patients were asked by their GP to participate in 
the study. Patients who gave written informed consent were randomly 
assigned to group O-oral daily treatment or to group I-IM conventional 
weekly treatment. Blocks of four were generated from computer soft-
ware. Each GP practice received two blocks (four O-oral group and four 
I-IM group) each packed in sealed and unlabelled envelopes. Once a 
patient had consented, the GP or his staff opened one envelope to reveal 
which group of the study the patient had been randomised to. Upon re-
quest, further blocks were available. 
Interventions 
Patients of group O-oral were instructed to ingest one tablet of 1000 µg 
cyanocobalamin daily (B12 “Ankermann”; Wörwag Pharma GmbH & 
Co, Böblingen, Germany) for 28 consecutive days supplied in a 7x4 
punch card with electronic adherence monitoring. Polymedication elec-
tronic monitoring system (POEMS) technology [29] was used to assess 
adherence to the oral VB12 intake. POEMS consists of a film with im-
printed electronic components that measure the electrical resistance and 
record the time of its changes when a loop is broken, i.e., when a cavity 
is emptied. A first punch card fitted with POEMS was handed out for 
14 days. A second identical punch card was handed out for a further 2 
weeks at the third visit 2 weeks later. Patients were instructed to return 
the punch cards for pill count and for the extraction of the electronic 
adherence data. Patients of the group I-IM received conventional sup-
plementation with weekly injections of 1000 µg hydroxocobalamin 
(Vitarubin® Depot 1000 µg / 1ml; Streuli Pharma AG, Uznach, Swit-
zerland, mixed with Lidocaine 1% 1 ml before injection). The treatment 
options were not blinded. 
Adherence outcomes 
For each patient in the group O-oral, we calculated two adherence rates: 
adherence with pill count, defined as the percentage of days with per-
formed intakes divided by the days with prescribed intakes, and dosing 
irregularities, defined as the percentage of days with 2 dosing events 
from the POEMS data. 
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Biomarker assessment 
Venous blood samples were drawn before the first administration (V0), 
and after 1 (V7), 2 (V14), and 4 weeks of treatment (V28). Blood sam-
ples were analysed by means of immunological assays on a Beckman 
Coulter DxC 860i (VB12), Roche cobas® 6000 (homocysteine, folic 
acid), and Abbott Architect i2000SR (holotranscobalamin). Methylma-
lonic acid was measured with liquid chromatography mass spectrome-
try (LC-MS/MS) on a Thermo Scientific UltiMate 3000 Rapid Separa-
tion LC coupled to an AB Sciex 5500 TripleQuad MS. Blood cell count 
was determined on a Beckman Coulter DxH 800. Normalisation of 
VB12-associated biomarkers was defined as a serum VB12 >258 
pmol/l, HoloTc >37 pmol/l, Hcy <15 πmol/l and MMA <270 nmol/l. 
Folate deficiency was defined as a serum value <9.1 nmol/l. GPs were 
informed about biomarker levels after V28. 
Patient preferences 
Preferences were determined before block randomisation (V0) and after 
4 weeks of treatment (V28), with use of a scenario-based approach. Pa-
tients were asked to select treatment by ticking tablets, syringes or no 
preference in a questionnaire, given that oral and IM substitution was 
equally effective. The questionnaire consisted of nine items focusing on 
factors influencing preference: pain, disgust, side effects, effectiveness, 
inconvenience, difficulties, time consumption, costs, and nonadherence 
to treatment schedule. Each item was to be answered twice for each 
therapy option (oral and IM). Answers could be given on a 10-point 
Likert scale. 
Sample size 
Sample size estimation was based on assumptions regarding outcomes 
after 4 weeks. Patients were expected to display baseline VB12 concen-
trations of 100–150 pmol/l. Based on published data, patients reach lev-
els of approximately 600 pmol/l with an estimated standard deviation 
of 120 pmol/l after treatment. A difference of 100 pmol/l between lev-
els after intramuscular or oral supplementation was deemed acceptable 
for noninferiority, on the presumption that this difference is clinically 
meaningless. 
With the hypothesis that there is no difference between the groups, 50 
patients were required to show with 90% confidence that the lower limit 
of a one-sided 95% confidence interval will be above the noninferiority 
limit of 100 pmol/l. 
Statistical analysis 
Values are given as mean ± standard deviation (SD), median with quar-
tiles and percentages where appropriate. Frequencies were analysed us-
ing chi‐square tests or Fishers test. The Mann‐Whitney test was used to 
compare numerical variables between two groups and the Kruskal-Wal-
lis test was used to compare between three groups. Spearman’s r was 
calculated to assess correlations between numerical variables and inter-
preted with the following criteria: 0–0.25 = little or no correlation; 
0.26–0.50 = small correlation; 0.51–0.75 = moderate to good correla-
tion, and >0.75 = very good to excellent correlation. A p-value 0.05 
was considered significant. 
Results 
Between November 2013 and December 2015, 37 patients (age 49.5 ± 
18.5 years; 60.5% women) were recruited for oral (n = 19) or IM (n = 
18) treatment. No patient reported any harms or side effects during the 
study period. Recruitment was terminated after an anticipated analysis 
showed sufficient biomarker response for both treatment options and an 
enormous difference between groups in mean VB12 values at V28 
(2442 pmol/l), leading to the rejection of the primary noninferiority hy-
pothesis for oral treatment. Post-hoc sample size estimation was based 
on VB12 outcomes at V28. Patients in group O-oral and group I-IM had 
VB12 levels of approximately 350 pmol/l with a standard deviation of 
120 pmol/l and 2700 pmol/l with a standard deviation of 2700 pmol/l, 
respectively. With the hypothesis that there is a difference between the 
groups, a total of 28 patients were required to ensure that the 90% con-
fidence interval includes the true difference between groups with an  
of 5%. The baseline characteristics were equally distributed between 
the two treatment groups (table 1).  
The study population contained patients with the following diagnosis 
or risk factors associated with VB12 deficiency: pernicious anaemia (n 
= 2), metformin intake (n = 2), use of acid lowering drugs (n = 4), veg-
etarian or low dietary intake of VB12-containing food (n = 18), diag-
nosed alcohol abuse or daily intake of alcohol (n = 4), and gastric sta-
pling (n = 1). No established risk factor for VB12 deficiency was iden-
tified in six patients. Distribution of risk factors was balanced between 
the groups (data not shown). 
A total of 38 electronic punch cards containing oral treatment were de-
livered, one of which was not returned (excluded from analysis) and 13 
only partially detected the removals because of technical problems. 
From the 518 expected events, 356 were recorded (31.3% missed data). 
Days with 2 dosing events occurred in 5.6% of all recordings. Average 
treatment adherence by pill count was 99.6% ± 1.1% 
Blood counts and levels of VB12, HoloTc, Hcy, MMA, folic acid, so-
dium, potassium, creatinine and liver enzymes did not differ at baseline 
(V0) between groups (table 1). Levels of VB12 and HoloTc were sig-
nificantly increased at V7, V14 and V28 compared with baseline for 
both groups (p <0.01) (table 2). For group I-IM at each assessment 
point, VB12 and HoloTc response was significantly higher (p <0.01, 
fig. 1) and the level of Hcy was significantly more reduced (p <0.01) 
compared with group O-oral. Reduction of Hcy levels compared with 
baseline was significant at V7 for group I-IM and at V28 for both 
groups (group O-oral p <0.05; group I-IM <0.01). MMA levels were 
significantly decreased compared with baseline at V7 for both groups 
(p <0.01) and did not differ between groups (fig. 1). Blood count and 
folic acid levels did not change significantly between V0 and V28 in 
both groups (data not shown). 
After 28 days of treatment, in group O-oral normalised VB12 levels 
were reached by 16 (84.2%) patients, normal Hcy levels by 14 (73.9%) 
patients and normal HoloTc and MMA levels by 19 (100%) patients 
(fig. 2). After 28 days of treatment in group I-IM, all 18 patients (100%) 
had normal VB12, HoloTc, Hcy and MMA levels. Percentage of pa-
tients with a normalisation of all biomarkers at V28 was significantly 
higher in group I-IM compared with group O-oral (100% vs 63.2%, p 
<0.05). 
At V0, VB12 or HoloTc did not correlate with Hcy or MMA within the 
study population. Within group O-oral a non-significant small correla-
tion between Hcy levels and VB12 was found at V7 (r = ˗0.369; p = 
0.12), V14 (r = ˗0.388; p = 0.10) and V28 (r = ˗0.341; p = 0.15) and 
between Hcy and HoloTc at V14 (r = ˗0.397; p = 0.10) and V28 (r = 
˗0.392; p = 0.10). Levels of VB12 or HoloTc did not correlate with 
MMA. Within group I-IM a moderate correlation was found for VB12 
and Hcy levels at V7 (r = ˗0.725; p <0.001), V14 (r = ˗0.507; p<0.05) 
and a small nonsignificant correlation at V28 (r = ˗0.254; p = 0.38). 
Levels of HoloTc and Hcy did not correlate nor did levels of MMA 
correlate with VB12 or HoloTc levels. Correlation between Hcy and 
creatinine levels was moderate for the whole study population at V0 (r 
= 0.522; p <0.001) and for the group O-oral at V28 (r = 0.491; p <0.05). 
A high correlation was observed for group I-IM at V28 (r = 0.713, p 
<0.001). 
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Table 1: Baseline characteristics in patients receiving oral or IM vitamin B12 substitution (n = 37). 
 Normal values  Group O-oral (n = 19) Group I-IM (n = 18) p-value 
Women (n)  % (n) 68.4% (n = 13) 55.6% (n = 10) 0.508 
Age (years)  Mean ± SD 47.3 ± 17.8 51.5 ± 19.6 0.543 
Body mass index (kg/m2)  Mean ± SD 27.3 ± 7.00 25.6 ± 4.20 0.715 
Vitamin B12 (pmol/l) >258 Mean ± SD 
Median (quartiles) 
158 ± 27.4 
164 (135/177) 
164 ± 20.1 
161 (152/178) 
0.578 
Holotranscobalamin (pmol/l) >37 Mean ± SD 
Median (quartiles) 
49.0 ± 17.7 
49.9 (32.1/63.2) 
50.1 ± 23.0 
43.1 (35.8/65.5) 
0.940 
Homocysteine (µmol/l) <15 Mean ± SD 
Median (quartiles) 
14.8 ± 5.80 
13.2 (10.9/16.7) 
13.0 ± 4.10 
13.4 (9.6/16.7) 
0.408 
Methylmalonic acid (nmol/l) <270 Mean ± SD 
Median (quartiles) 
304 ± 172 
284 (160/379) 
321 ± 183 
249 (183/332) 
0.757 
Haemoglobin (g/l) 120–160 (women) 
135–175 (men) 
Mean ± SD 
Median (quartiles) 
138 ± 13.1 
136 (127/145) 
136 ± 11.8 
137 (127/141) 
0.822 
Mean corpuscular volume (fl) 85–101 Mean ± SD 
Median (quartiles) 
91.7 ± 6.40 
91 (89/96) 
93.7 ± 6.10 
93 (90/95) 
0.663 
Mean corpuscular haemoglobin (pg) 28–33 Mean ± SD 
Median (quartiles) 
30.7 ± 2.10 
31 (30/32) 
31.2 ± 2.00 
31 (30/32) 
0.799 
Folic acid (nmol/l)  9.1–42.4 Mean ± SD 
Median (quartiles) 
16.2 ± 5.80 
16.6 (11.8/18.4) 
17.6 ± 5.80 
16.7 (13.7/22.0) 
0.558 
Sodium (mmol/l) 136–145 Mean ± SD 
Median (quartiles) 
140 ± 1.9 
140 (139/141) 
140 ± 1.7 
141 (139/141) 
0.775 
Potassium (mmol/l) 3.5–5.1 Mean ± SD 
Median (quartiles) 
4.6 ± 1.0 
4.2 (4.1/4.5) 
4.2 ± 0.3 
4.2 (4.0/4.3) 
0.298 
Creatinine (µmol/l) 49–90 (women) 
64–104 (men) 
Mean ± SD 
Median (quartiles) 
74 ± 14.1 
72 (64/83) 
74 ± 12.7 
73 (65.25/79.5) 
0.916 
Alanine aminotransferase (U/l)) <55 Mean ± SD 
Median (quartiles) 
8.0 ± 8.6 
8.0 (0/11) 
6.6 ± 5.5 
6.5 (0/12) 
0.964 
Aspartate aminotransferase (U/l) 5–34 Mean ± SD 
Median (quartiles) 
25.9 ± 5.9 
24 (21/32) 
22.6 ± 3.9 
22 (20/25) 
0.105 
Gamma-glutamyltransferase (U/l) 9–46 Mean ± SD 
Median (quartiles) 
39.2 ± 53.2 
15 (10/46) 
19.5 ± 10.5 
17.5 (10/23.75) 
0.916 
SD = standard deviation 
  
 
 
Table 2: Serum concentrations of vitamin B12, holotranscobalamin, homocysteine and methylmalonic acid at baseline (V0) and after 7, 14 and 28 days of treatment (V7, V14 
and V28). 
 
Group 
Mean concentration (95% confidence interval) 
V0 V7 V14 V28 
VB 12 (pmol/l) O-oral 158 (145–172) 304 (250–357) 319 (284–355) 354 (298–410) 
I-IM 164 (154–174) 1088 (934–1236) 1897 (1219–2574) 2796 (1277–4314) 
p-value 0.58 <0.001 <0.001 <0.001 
HoloTc (pmol/l) O-oral 49.0 (40.4–57.5) 148 (109–187) 144 (115–173) 156 (116–196) 
I-IM 50.1 (38.7–61.6) 244 (200–288) 495 (373–617) 1269 (103–2435) 
p-value 0.94 <0.01 <0.001 <0.001 
Hcy (µmol/l) O-oral 14.8 (12.0–17.7) 14.6 (11.7–17.3) 14.3 (11.4–17.3) 13.8 (10.7–16.8) 
I-IM 13.0 (11.0–15.1) 9.5 (8.2 – 11.0) 9.0 (7.4–10.7) 8.5 (7.1–9.8) 
p-value 0.41 <0.001 <0.001 <0.001 
MMA (nmol/l) O-oral 304 (219–390) 188 (148–227) 187 (151–223) 168 (134–202) 
I-IM 321 (215–427) 172 (135–208) 161 (127–197) 156 (121–190) 
p-value 0.76 0.53 0.16 0.51 
Hcy = homocysteine; HoloTc = holotranscobalamin; MMA = methylmalonic acid; VB12 = vitamin B12 
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Figure 1: Biomarker levels 
(mean and 95 confidence in-
tervals [CI]) at baseline (Visit 
0), Visit 7, Visit 14 and Visit 28 
for group O-oral treatment 
() and group I-IM treatment 
(►). Grey areas indicate sub-
therapeutic levels, dotted 
lines indicate threshold values 
for biomarker normalisation. 
(A) Mean serum vitamin B12 
(VB12) levels, dotted line at 
258 pmol/l; (B) mean holo-
transcobalamin (HoloTc) lev-
els, dotted line at 37 pmol/l; 
(C) mean homocysteine (Hcy) 
levels, dotted line at 15 
πmol/l; (D) mean methylmalo-
nic acid (MMA) levels, dotted 
line at 270 nmol/l. 
 
 
Before randomisation, 17 patients preferred oral treatment (45.9%) and 
eight patients preferred IM treatment (21.6%). Twelve patients (32.4%) 
had no preference. Concerns were compared between patients grouped 
by preference. For the patients who preferred tablets, therapy with sy-
ringes would raise more concerns about the pain (p = 0.001), disgust (p 
= 0.004), side effects (p = 0.017), inconvenience (p = 0.001), difficulties 
(p = 0.001) and time consumption (p = 0.001). Patients preferring IM 
treatment indicated their concerns about forgetting to take the medicine 
regularly (addressed as nonadherence to treatment schedule) (p = 
0.018), inconvenience (p = 0.024) or higher time consumption when 
taking tablets (p = 0.001) (table 3). 
Nine patients (24.3%) changed their preference after treatment. Of the 
patients who were allocated to the nonpreferred administration group, 
20% changed their mind regardless of whether they were exposed to 
oral or IM treatment: patients who received oral treatment changed their 
mind in favour of oral treatment (100%) and patients receiving IM treat-
ment changed their mind in both direction at V28. Patients who pre-
ferred oral treatment and were assigned to group O-oral maintained 
their preference (100% congruence). Patients who preferred IM treat-
ment and obtained parenteral treatment changed their preference at V 
28 (0% congruence, see figure S1 in the appendix). 
 
 
 
Figure 2: Proportion of patients with normalised VB12-associated biomarkers after 28 
days of treatment administered by the oral (n = 19; white bar) or IM route (n = 18; 
grey bar). 
* indicates significant difference (p< 0.05). Hcy = homocysteine; HoloTc = holotrans-
cobalamin; MMA = methylmalonic acid; VB12 = vitamin B12 
 
  
Original article   Swiss Med Wkly. 2017;147:w14421 
Swiss Medical Weekly · PDF of the online version · www.smw.ch   Page 6 of 9 
Published under the copyright license "Attribution - Non-Commercial - No Derivatives 4.0".  
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html. 
Table 3: Patients’ answers to nine items known to influence treatment preference, before randomisation. Answers are sorted according to the first question “Which treat-
ment do you prefer?” tablets / syringes / no preference. Each item was to be answered twice for therapy with syringes and with tablets. The higher the score the higher the 
anticipated effect of the corresponding item on a Likert scale 1–10. Data are given as mean ±SD. A p-value <0.05 indicates a significant difference between the group with the 
highest values versus the group with the lowest values. 
Item  Prefers tablets  
(n = 17) 
Prefers syringes 
(n = 8) 
No preference 
(n = 12) 
p-value between three 
groups 
Pain Syringes 
Tablets 
5.7 ± 2.0 
1.0 ± 0.0 
3.1 ± 1.6 
2.1 ± 2.2 
2.6 ± 1.2 
1.1 ± 0.3 
0.001 
0.101 
Disgust Syringes 
Tablets 
5.9 ± 2.4 
3.1 ± 1.7 
3.1 ± 2.2 
4.6 ± 2.3 
3.2 ± 2.4 
2.5 ± 1.4 
0.004 
0.078 
Side effects Syringes 
Tablets 
4.2 ± 2.6 
2.4 ± 1.3 
2.1 ± 1.8 
2.8 ± 2.5 
2.3 ± 1.5 
2.3 ± 1.5 
0.017 
0.950 
Effectiveness of the treatment Syringes 
Tablets 
8.4 ± 1.5 
7.8 ± 2.2 
9.0 ± 1.1 
6.9 ± 2.3 
8.8 ± 1.3 
8.0 ± 1.5 
0.740 
0.454 
Inconvenience Syringes 
Tablets 
6.8 ± 1.8 
2.7 ± 1.5 
2.6 ± 1.4 
4.9 ± 2.4 
2.3 ± 1.2 
2.3 ± 2.0 
0.001 
0.024 
Difficulties Syringes 
Tablets 
4.7 ± 2.7 
1.7 ± 1.7 
1.8 ± 1.8 
1.9 ± 1.6 
1.4 ± 0.7 
1.3 ± 0.6 
0.001 
0.808 
Time consumption Syringes 
Tablets 
7.0 ± 2.6 
1.2 ± 0.5 
4.1 ± 2.8 
2.6 ± 0.9 
2.4 ± 1.0 
1.3 ± 0.7 
0.001 
0.001 
Costs Syringes 
Tablets 
4.5 ± 2.6 
2.8 ± 1.7 
3.9 ± 3.1 
2.6 ± 1.8 
3.5 ± 2.7 
2.4 ± 2.7 
0.503 
0.504 
Nonadherence to treatment schedule Syringes 
Tablets 
3.3 ± 2.6 
2.4 ± 2.6 
3.8 ± 2.8 
4.3 ± 1.7 
2.6 ± 2.6 
2.7 ± 2.9 
0.390 
0.018 
 
Discussion 
In our study, levels of VB12 and HoloTc were significantly increased 
and levels of Hcy and MMA significantly decreased after 28 days of 
treatment with high-dose VB12 administered by either the oral or IM 
route. These findings are in line with other trials, of which two assessed 
the effect of oral high-dose VB12 substitution (1000 µg cyanocobala-
min) vs placebo [24, 30], whereas three other randomised, controlled 
trials compared cyanocobalamin therapy administered orally (1000–
2000 µg) or parenterally (1000 µg cyanocobalamin) [22, 23, 31]. 
In contrast to prior studies, we observed an exaggerated response after 
IM administration and therefore the hypothesis for noninferiority of 
oral in comparison to IM treatment had to be rejected. Because we used 
electronic punch cards and monitored an almost perfect intake of tablets 
(99.6% adherence), nonadherence can be ruled out as a contributor to 
the less pronounced response of VB12, HoloTc and Hcy in patients fol-
lowing oral administration. Thus, the enormous difference must have a 
chemical or physiological explanation. One reason might be the use of 
hydroxocobalamin, a physiological intermediate form that is more 
available to cells than other cobalamin forms [32]. In children with 
VB12 deficiency, one injection of 400 µg hydroxocobalamin resulted 
in improvement in motor function and cobalamin repletion [33]. Addi-
tionally, hydroxocobalamin is retained in plasma longer than equivalent 
doses of cyanocobalamin, which allows less frequent dosing. However, 
owing to its low stability, hydroxocobalamin is less suited for oral sup-
plementation, whereas cyanocobalamin is best suited for oral supple-
mentation as it is a more stable and inexpensive [34]. Surprisingly, sus-
tainability of biomarker response after IM hydroxocobalamin admin-
istration has been poorly described. In one study among 8 patients with 
VB12 levels below 80 pg/ml (59.4 pmol/l), VB12 levels between 300 
and 1100 pg/l (221–812 pmol/l) were obtained 10 days after the injec-
tion of 1000 µg hydroxocobalamin. The levels fell below 200 pg/l (148 
pmol/l) between 4 and 10 weeks later [35]. In our study, wide interin-
dividual variation in VB12 and HoloTc responses was observed within 
the IM group, which corresponds to the wide interindividual variations 
in hydroxocobalamin pharmacokinetics reported by others [36, 37]. 
To our knowledge, there are no reports of high levels of VB12 and 
HoloTc with daily oral VB12 substitution over a longer treatment pe-
riod similar to those we observed after IM treatment. In one study with 
high-dose oral substitution of VB12 for 3 months, patients with initially 
low levels of VB12 (186 ± 56 pmol/l) reached higher VB12 levels 
(mean 477 pmol/l) than we observed after 28 days of treatment, albeit 
levels of HoloTc (183 pmol/l), Hcy (13.4 µmol/l) and MMA (0.23 
µmol/ 230 nmol/l) were comparable to the levels we observed after 7 
days (HoloTc and MMA) and after 28 days (Hcy) of oral treatment [30]. 
Continuation of treatment for up to 6 months did not result in additional 
significant changes in VB12, HoloTc, Hcy and MMA [30]. A further 
study observed a plateau in serum VB12 levels with a mean of 1164 
pg/ml (858 pmol/l) after 3 months when patients received a loading 
dose of 1000 µg hydroxocobalamin and a subsequent 18 months of 
treatment with 1000 µg oral cyanocobalamin [38]. These findings sug-
gest that continuous oral treatment with high dose VB12 reaches satu-
ration in serum VB12 levels after 3 months of treatment. In our study, 
three patients did not have normal levels of VB12 after oral treatment. 
However, two out of those three patients had VB12 levels above the 
normal range at V14, which slightly decreased afterwards. In the ab-
sence of any rational explanations (e.g., patients did not stop treatment 
prematurely), results indicate that time to VB12 saturation after therapy 
and the level of saturation may vary between patients. The other patient 
responded slowly to oral substitution, probably owing to the underlying 
cause of VB12 deficiency, which was gastric stapling (VB12 levels at 
V0 and V28: 108 pmol/l and 182 pmol/l, respectively). Furthermore, 
the active part of vitamin B12, HoloTc, was normalised in all patients 
at V28. Pernicious anaemia could be another explanation for nonre-
sponse in the O-oral group. However, because all patients had some 
kind of response or a physiological rationale for a slower response (i.e. 
gastric stapling), this explanation is very unlikely. 
Five patients in the oral group did not reach normalised Hcy levels at 
V28. However, there is as yet no agreement on normal ranges for 
VB12-associated biomarkers [39]. Hcy lacks specificity, and response 
may be confounded by folic acid and vitamin B6 deficiency, as well as 
by renal insufficiency, liver insufficiency and genetic abnormalities. 
Additionally, Hcy levels are influenced by lifestyle factors, such as con-
sumption of coffee, alcohol and tobacco [40]. The incomplete normali-
sation of Hcy levels in our cohort could be explained in two patients 
with folic acid deficiency or diagnosed renal insufficiency, respec-
tively. Additionally, renal function might have affected normalisation 
in other patients as well, indicated by the correlation between Hcy and 
creatinine. Compared with IM treatment, decrease in Hcy levels was 
slower with oral treatment. Other studies have also found Hcy levels to 
respond slowly to oral treatment [24], with a trend to further decrease 
over a period of 18 months [38].  
A negative concentration-effect relationship was observed for Hcy and 
VB12 in the group I-IM. A trend towards similar correlation between 
low Hcy levels and high VB12 levels was observed for group O-oral. 
A stronger concentration-effect relationship may be observed in pa-
tients with a more pronounced deficiency of VB12-associated bi-
omarkers. Before drawing conclusions on concentration-effect relation-
Original article   Swiss Med Wkly. 2017;147:w14421 
Swiss Medical Weekly · PDF of the online version · www.smw.ch   Page 7 of 9 
Published under the copyright license "Attribution - Non-Commercial - No Derivatives 4.0".  
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html. 
ship between VB12 and Hcy, results should be verified in a bigger sam-
ple of anaemic patients with consideration of further factors such as re-
nal function and lifestyle. 
Interestingly, the functional biomarkers MMA and Hcy did not respond 
consistently in either group. Patients in both groups reached normal 
MMA levels at V7. Hcy levels in the I-IM group were decreased at V7 
too, whereas levels in O-oral-group were decreased at V28, and signif-
icantly higher at each assessment point compared with the I-IM group. 
The different enzyme systems converting Hcy and MMA in the human 
body might explain the observed difference in functional biomarker re-
sponse between groups. In vitro studies showed that hydroxocobalamin 
induces the activation of one of these enzyme systems (methionine syn-
thase) more strongly and quickly than cyanocobalamin [41]. 
In summary, supratherapeutic levels were observed for VB12 and 
HoloTc after the IM treatment with hydroxocobalamin, which might 
never be reached through oral substitution. Additionally, normalisation 
of all biomarkers was significantly higher in group I-IM compared with 
group O-oral (100% vs 63.2%, p<0.05). However, incomplete response 
in group O-oral was limited to VB12 and Hcy. Therefore, the benefit of 
such an exaggerated response after IM injection seems limited to a prac-
tical advantage in the form of fewer administrations, i.e. longer treat-
ment intervals and in the case of symptomatic patients needing rapid 
normalisation of VB12-associated biomarkers. A large prospective ran-
domised controlled trial comparing high-dose oral with intramuscular 
cyanocobalamin in elderly patients is currently underway (PMID: 
22650964, NCTNCT 01476007). This study is expected to report on 
long-term oral and IM VB12 substitution (8, 26 and 52 weeks). How-
ever, no reports on short-term biomarker response or patient prefer-
ences are expected. Further studies are required to assess the effects of 
different cobalamin forms on biomarker response and on clinical out-
comes. Accordingly, observed differences between cobalamin forms 
should be incorporated into guidelines for treatment of VB12 defi-
ciency. 
As expected, patients preferred oral treatment to IM treatment, before 
the assignment to treatment as well as after treatment completion. Our 
findings are in line with reports from two studies on patient preferences 
in relation to oral VB12 treatment [38, 42]. In a study in primary care, 
83% of patients preferred oral to IM treatment [38]. In another study 
involving patients receiving VB12 as injection and willing to try oral 
administration, the majority were satisfied with the switch and wished 
to remain permanently on oral therapy. Important factors for switching 
to oral therapy were the disadvantage of injections and their association 
with many visits to their healthcare providers, higher costs and the con-
venience of oral treatment [42]. We also found time consumption and 
inconvenience of IM treatment as important factors in favour of oral 
treatment. 
There was a slight change in patient preferences after receiving oral 
therapy (n = 2, 10.5%), whilst changes occurred only in favour of oral 
treatment. This may indicate that patients appreciate the route of ad-
ministration more after experiencing oral treatment at first hand. After 
experiencing IM treatment, 11 patients (38.9%) changed their prefer-
ence in various directions. This is interesting in view of the pretreatment 
attitudes towards important factors associated with patient preferences, 
regarding a therapy with syringes (n = 6) and regarding a therapy with 
tablets (n = 3). These findings suggest that patients may have more prej-
udice regarding syringes, which may explain the numerous and various 
changes after experiencing IM treatment. 
Given the exaggerated response after IM treatment, the required fre-
quency of injections with hydroxocobalamin in clinical practice may be 
lower in patients with mild VB12 deficiency, which may augment the 
preference for IM administration. Additional research with validated 
methods is needed to gain an insight into the patient preferences, espe-
cially when therapeutic options with comparable efficacy and safety are 
available. 
Limitations of the study include the fact that we enrolled patients 
mostly without haematological symptoms and not necessarily abnormal 
functional biomarkers. Therefore, patients in our study were less likely 
to respond to VB12 substitution, which affects our ability to generalise 
our results to a symptomatic, anaemic, VB12-deficient population. Sec-
ond, the questionnaire we used to assess patients’ preferences consisted 
of re-used questions from several assessment tools but was not vali-
dated completely as an entity. Nevertheless, the single questions can be 
judged valid for retrieving patient preferences. Additionally, we did not 
assess patient preferences for maintenance therapy and therefore cannot 
evaluate whether preferences would change in this long-term situation. 
However, it seems justified to re-evaluate treatment 1 month after ini-
tiation, irrespective of treatment schedule as received treatment is 
strongly suspected to influence attitudes and ultimately patient prefer-
ences. Third, we had a high proportion of technical issues leading to a 
loss of one third of the electronically gained adherence data; therefore, 
days with more dosing events might have occurred more frequently, as 
suggested by our calculations. However, this technical drawback had 
no impact on the calculation of adherence based on the conventional 
pill count method. Last, we stopped the study prematurely after an an-
ticipated analysis and thus obtained a small sample size. However, the 
normalised levels reached in both groups did not justify continuing the 
study since the hypothesis was rejected with the small number of pa-
tients. 
Conclusion 
Differences in VB12, HoloTc and Hcy levels between groups were 
higher than expected. Therefore, the hypothesis of noninferiority of oral 
treatment had to be rejected. However, HoloTc and MMA were nor-
malised in all patients and VB12 and Hcy in the majority of patients 
within group O-oral after 1 month of treatment. The clinical benefit of 
the exaggerated biomarker response after IM treatment within a typical 
primary care population is questionable. Midterm biomarker effects and 
patient preferences should be considered in the choice of therapeutic 
scheme. Initial rating in favour of either IM or oral therapy can change 
over time and justifies repeated re-evaluation of patient preferences. 
However, the majority of patients preferred oral treatment before and 
after the study, indicating the need for a high-dose oral VB12 prepara-
tion in Switzerland. Further research may help to evaluate which route 
of administration, oral vs IM, of long-term VB12 treatment, will be ap-
propriate to yield a sustained biomarker response. 
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Appendix: Supplementary figure 
 
 
Figure S1: Patients preferences before and after 28 days of treatment administered by the oral (n = 19) or IM route (n = 18). 
 
 
 
